Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Apaziquone as Surgical Adjuvant for NMIBC
NCT02563561Phase 3Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Oct 2015
- Primary completion
- Mar 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apaziquone in non-muscle-invasive bladder cancer (NMIBC), sponsored by Spectrum Pharmaceuticals, Inc.. Started Oct 2015; status: terminated.
02
Drugs
apaziquone
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02563561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563561.